Furkat Sobirov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Furkat Sobirov has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Ainur Sadykova
Department of Infectious and Tropical Diseases, Kazakh National Medical University Named After S.D. Asfendiyarov, Almaty 050044, Kazakhstan
1 shared publication - Amir Arsalan Ghahari
Department of Mycobacteriology and Pulmonary Research Pasteur Institute of Iran Tehran Iran
1 shared publication - Gulrukh Indiaminova
Department of Obstetrics and Gynaecology No. 3 Samarkand State Medical University Samarkand Republic of Uzbekistan
1 shared publication - Mirzamakhmud Shadmanov
Department of Urology Andijan State Medical Institute Andijan Republic of Uzbekistan
1 shared publication - Mukaddas Xusanova
Department of Anatomy Alfraganus University Tashkent Republic of Uzbekistan
1 shared publication - Patkhiddin Nishonov
Department of Practical French Language Studies Uzbekistan State World Language University Tashkent Uzbekistan
1 shared publication
Latest Publications
- Open Access
- 29 July 2026
- Published by Wiley in Microbiologyopen
- Vol. 15 (4)
Decoding Akkermansia muciniphila Effector Biology: From Microbial Molecules to Host Outcomes
Akkermansia muciniphila is increasingly linked to host metabolic, immune, and neurobehavioral phenotypes, yet taxon‐level associations are often inconsistent across studies and disease contexts. This review advances an effector‐centered framework to explain how A. muciniphila acts through host‐facing molecules, including outer membrane and secreted proteins such as Amuc_1100 (pilus‐associated signaling, PAS) and P9, extracellular vesicles (EVs) and outer membrane vesicles (OMVs), and shed cell‐envelope fragments and lipids. We synthesize evidence spanning barrier biology, immunometabolic regulation, infection and inflammatory injury, cancer immunology, and microbiota–gut–brain axis research. Across models, effectors modulate the mucus and epithelial barrier to limit translocation and dampen Toll‐like receptor (TLR) signaling, but mucus‐active enzymes or antigenic epitopes may also create liabilities in susceptible hosts. Defined effectors can reproduce key whole‐cell effects: in high‐fat diet (HFD)/carbon tetrachloride (CCl4) liver injury, vesicle preparations matched or exceeded pasteurized bacteria; Amuc_1100 maps to immune reprogramming and barrier signaling; and P9 links microbial cues to glucagon‐like peptide 1 (GLP‐1) release. Key gaps include physiological dose realism, equivalence across colony‐forming units (CFU) and protein or vesicle doses, strain and culture‐condition dependence of effector expression, and limited human data for brain‐relevant endpoints. Effector‐defined preparations and engineered delivery systems may improve standardization and safety, but translation will require rigorous characterization, dose‐response validation, and mechanism‐linked biomarkers.
- 29 July 2026
- Published by Wiley in Microbiologyopen
- Vol. 15 (4)
Open AccessDecoding Akkermansia muciniphila Effector Biology: From Microbial Molecules to Host Outcomes
Akkermansia muciniphila is increasingly linked to host metabolic, immune, and neurobehavioral phenotypes, yet taxon‐level associations are often inconsistent across studies and disease contexts. This review advances an effector‐centered framework to explain how A. muciniphila acts through host‐facing molecules, including outer membrane and secreted proteins such as Amuc_1100 (pilus‐associated signaling, PAS) and P9, extracellular vesicles (EVs) and outer membrane vesicles (OMVs), and shed cell‐envelope fragments and lipids. We synthesize evidence spanning barrier biology, immunometabolic regulation, infection and inflammatory injury, cancer immunology, and microbiota–gut–brain axis research. Across models, effectors modulate the mucus and epithelial barrier to limit translocation and dampen Toll‐like receptor (TLR) signaling, but mucus‐active enzymes or antigenic epitopes may also create liabilities in susceptible hosts. Defined effectors can reproduce key whole‐cell effects: in high‐fat diet (HFD)/carbon tetrachloride (CCl4) liver injury, vesicle preparations matched or exceeded pasteurized bacteria; Amuc_1100 maps to immune reprogramming and barrier signaling; and P9 links microbial cues to glucagon‐like peptide 1 (GLP‐1) release. Key gaps include physiological dose realism, equivalence across colony‐forming units (CFU) and protein or vesicle doses, strain and culture‐condition dependence of effector expression, and limited human data for brain‐relevant endpoints. Effector‐defined preparations and engineered delivery systems may improve standardization and safety, but translation will require rigorous characterization, dose‐response validation, and mechanism‐linked biomarkers.